Bao Pharmaceutical

Bao Pharma is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, dedicated to the development of high-end recombinant protein drugs and synthetic biology-based therapeutics. Established in 2019, the company focuses on addressing unmet medical needs through its proprietary enzyme engineering and protein expression platforms. Its lead product candidate, B001, is a recombinant human hyaluronidase designed to facilitate the subcutaneous administration of large-molecule biologics. The pipeline also includes advanced programs for infertility treatment and metabolic disorders, such as recombinant human follicle-stimulating hormone and urate oxidase. Bao Pharma has secured significant backing from prominent investors like Hillhouse Capital and Lilly Asia Ventures to accelerate its clinical programs and manufacturing capabilities.